COVID-19 is caused by SARS-CoV-2, and immunity can be achieved either by native or preventive immunization of the population. Thus far, the US Food and Drug Administration has issued an emergency use authorization for 3 novel COVID-19 vaccines.¹ On December 11, 2020, the BNT162b2 (Pfizer-BioNTech) vaccine was the first to achieve this authorization, and millions of people worldwide have been vaccinated with it.²

Recently, several papers referred to the association of different bacteria with lupus in mice and humans. This is the first report to demonstrate the effect of a compound derived from helminths on the induction of remission in mice with lupus and its association with a bacterial change. We show that several genera, including Akkermansia , are associated with clinical and serological parameters of lupus, while other genera, including butyrate-producing bacteria, are associated with amelioration of disease following tuftsin and phosphorylcholine treatment.